Understanding the Role of Immunoglobulins in Multiple Myeloma

Video

At CURE’s Educated Patient Summit on Multiple Myeloma Dr. Shebli Atrash had the chance to further discuss with CURE what questions he addresses most when patients with multiple myeloma undergo diagnostic testing.

For patients with multiple myeloma, the treatment journey often begins with questions and trepidation as they start to understand their disease during the long process of diagnostic testing and staging. However, this staging does not need to be a mystery to patients, which is why Shebli Atrash, MD, MS, broke down how diagnostic testing works and what patients can expect from it at CURE’s Educated Patient Summit on Multiple Myeloma, held Dec. 14, in Charlotte, North Carolina.

Atrash, from the Levine Cancer Institute plasma cell disorder program, also had the chance to sit down with CURE and discuss in detail the role immunoglobulins play in the presentation of multiple myeloma and how he addresses common questions patients have about them.

TRANSCRIPTION

Immunoglobulins are proteins, but proteins produced from plasma cells. Plasma cells are the cells that cause multiple myeloma that live inside the bones and they help us fight infections. It's not related to how much protein patients eat, I get this question all the time, it's not produced by the liver it's produced by plasma cells and those proteins, in general, help us treat infections.

However, in multiple myeloma we have only one type of those proteins going up that's why we call it mono-clonal, mono stands for 1, and this type goes up regardless whether we have an infection or not. So, that's where we focus on and we call this a surrogate marker for multiple myeloma burden in the disease. Even so, we still have to see how much plasma cells are still left inside the bone marrow with bone marrow biopsies.

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
Woman with dark brown hair and pink lipstick wearing a light pink blouse with a light brown blazer. Patients should have conversations with their providers about treatments after receiving diagnoses.
Man in a navy suit with a purple tie. Dr. Saby George talks to CURE about how treatment with Opdivo could mitigate disparities in patients with kidney cancer.
Dr. Kim in an interview with CURE
Dr. Barzi in an interview with CURE
Related Content